My New Year’s resolution is pretty much the same as last year’s – keep buying dirt-cheap FTSE 100 shares. Unlike most of my resolutions, I find this one easy to stick to.
Last year, I bought three good blue-chip stocks on bad news, thinking they looked good value with a long-term view. In the short term, they’ve continued to struggle.
Spirits giant Diageo (LSE: DGE) started 2024 on a downer, still reeling from a shock drop in sales across its Latin America and Caribbean markets.
I’ll drink to a Diageo comeback
The share price is down 12% this year, and 22% over five years. Inflation has hit demand for its premium brands, persuading drinkers to downgrade to cheaper rivals.
Plus there’s an underlying threat that younger people are drinking less. Even the stunning success of Guinness and its alcohol-free spin off Guinness 0.0, couldn’t arrest the decline.
Diageo’s shares look reasonable value with a price-to-earnings ratio of 18.07. That’s down from 24 times before recent troubles hit. The yield is solid but unspectacular at 3.17%.
If inflation eases, Diageo should capitalise, helped by its strong pricing power and broad market reach. I’m expecting a solid recovery in 2025. No guarantees though.
Shares in commodities giant Glencore (LSE: GLEN) are down almost 25% this year due to falling demand for metals and minerals, particularly from China.
The natural resources sector is highly cyclical, and the Glencore share price could just as easily jump 25% next year. Any recovery may be bumpy though. China is in a pickle, despite repeated stimulus plans. If interest rates and inflation remain high, Glencore could disappoint again.
In the longer run, I’m much more upbeat. Glencore should benefit from the shift to electric vehicles and renewable energy, which will drive demand for copper, nickel and cobalt, all of which it produces. Its reliance on coal poses long-term ESG risks though.
I fancy Glencore over GSK
The shares look good value with a P/E of 10.12. I’m hoping the modest trailing yield of 2.85% will be topped up by one-off payments and share buybacks.
I took advantage of a dip in the GSK (LSE: GSK) share price to snap up the pharmaceuticals and vaccine giant, only to see it slide further.
GSK is down 7.6% over 12 months, and has fallen 28% over five years. That’s a poor showing from a supposedly defensive stock.
A shadow hung over GSK for much of the year, in the shape of US litigation over withdrawn heartburn treatment Zantac. When that shadow lifted it was replaced by another one, with US President-elect Donald Trump limbering up to play hardball with big pharma.
Recent restructuring efforts, including the spin-off of its consumer health business Haleon, have allowed the board to refocus on its core pharmaceuticals and vaccine operations.
GSK’s pipeline of new drugs and vaccines is promising, but we’ve been waiting a long time for that to pay off. The dividend has suffered as the board pumps money into R&D.
The trailing yield has climbed to 4.33%, but that’s mostly due to the falling share price. Of the three, I think Diageo is best placed for 2025. Glencore and GSK should also rocket at some point, but I may have to be more patient.
The post 3 cheap FTSE 100 shares that could rocket in 2025! appeared first on The Motley Fool UK.
AI Revolution Awaits: Uncover Top Stock Picks for Massive Potential Gains!
Buckle up because we’re about to dive headfirst into the electrifying world of AI.
Imagine this: you make a single savvy investment in some cutting-edge technology, then kick back and watch as it revolutionises entire industries and potentially even lines your pockets.
If the mere thought of riding this AI wave excites you and the prospect of massive potential returns gets your pulse racing, then you’ve got to check out this Motley Fool Share Advisor report – ‘AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!
And here’s the kicker – we’re giving you an exclusive peek at ONE of these top AI stock picks, absolutely free! How’s that for a bit of brilliance?
Get your free AI stock pick
More reading
“ARK appoints Warren Buffett as CEO” (and other headlines investors won’t see in 2025…)
Here’s why 2025 could be make-or-break for this FTSE 100 stock
How to invest £20,000 in 2025 to generate safe passive income
3 of the best British shares to consider buying for 2025
An investor could start investing with just £5 a day. Here’s how
Harvey Jones has positions in Diageo Plc, GSK, and Glencore Plc. The Motley Fool UK has recommended Diageo Plc, GSK, and Haleon Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
